Science Explorer Back to mapMap
Discussion
Company · Gaithersburg · United States

NexImmune (United States)

neximmune.comROR OpenAlex
Research works
18
◆ 1% vs 2018-21
Citations
293
16.6 per fractional work
Top-10% rate
8.2%
all institutions 10.0%
Open access
52%
world 40%
International
15%
world 18%
NexImmune (United States)

Not ranked overall: NexImmune (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does NexImmune (United States) work in?

In all years, 61% of research at NexImmune (United States) is in Life Sciences, 35% in Health Sciences. Its largest fields are Biochemistry, Genetics and Molecular Biology (34%), Medicine (33%), Immunology and Microbiology (25%). It does 2.4× the world's share of Life Sciences.

Life Sciences: 11 fractional works · 60.9% of its workBiochemistry, Genetics and Molecular Biology: 6 fractional works · 33.6% of its workMolecular Biology: 3 fractional works · 16.2% of its workGenetics: 1 fractional works · 8.0% of its workCell Biology: 0 fractional works · 2.2% of its workBiotechnology: 0 fractional works · 1.9% of its workCancer Research: 0 fractional works · 1.9% of its workClinical Biochemistry: 0 fractional works · 1.9% of its workBiochemistry: 0 fractional works · 1.0% of its workPhysiology: 0 fractional works · 0.6% of its workImmunology and Microbiology: 4 fractional works · 25.3% of its workImmunology: 4 fractional works · 24.4% of its workVirology: 0 fractional works · 1.0% of its workNeuroscience: 0 fractional works · 1.6% of its workNeurology: 0 fractional works · 1.0% of its workCellular and Molecular Neuroscience: 0 fractional works · 0.6% of its workAgricultural and Biological Sciences: 0 fractional works · 0.3% of its workAgronomy and Crop Science: 0 fractional works · 0.3% of its workHealth Sciences: 6 fractional works · 35.2% of its workMedicine: 6 fractional works · 33.4% of its workOncology: 3 fractional works · 16.4% of its workEpidemiology: 1 fractional works · 5.0% of its workPhysiology: 1 fractional works · 4.0% of its workRadiology, Nuclear Medicine and Imaging: 0 fractional works · 2.7% of its workImmunology and Allergy: 0 fractional works · 1.9% of its workHematology: 0 fractional works · 1.0% of its workTransplantation: 0 fractional works · 1.0% of its workPulmonary and Respiratory Medicine: 0 fractional works · 0.7% of its workObstetrics and Gynecology: 0 fractional works · 0.6% of its workSurgery: 0 fractional works · 0.2% of its workHealth Professions: 0 fractional works · 1.8% of its workGeneral Health Professions: 0 fractional works · 1.4% of its workEmergency Medical Services: 0 fractional works · 0.3% of its workPhysical Sciences: 1 fractional works · 3.7% of its workEngineering: 0 fractional works · 1.9% of its workBiomedical Engineering: 0 fractional works · 1.9% of its workEnvironmental Science: 0 fractional works · 1.9% of its workHealth, Toxicology and Mutagenesis: 0 fractional works · 1.9% of its workSocial Sciences: 0 fractional works · 0.2% of its workSocial Sciences: 0 fractional works · 0.2% of its workSociology and Political Science: 0 fractional works · 0.2% of its workALL ITS WORKNexImmune (UnitedStates)18fractional works, all years
Life Sciences61%Physical Sciences4%Health Sciences35%Social Sciences0%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 9 fields, with their numbers
    1. Biochemistry, Genetics and Molecular Biology633.6%
    2. Immunology and Microbiology425.3%
    3. Neuroscience01.6%
    4. Agricultural and Biological Sciences00.3%
    1. Medicine633.4%
    2. Health Professions01.8%
    1. Engineering01.9%
    2. Environmental Science01.9%
    1. Social Sciences00.2%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Who are the top researchers at NexImmune (United States)?

Ranked on the quality score, David Langan and Lauren Suarez lead among researchers whose main affiliation is NexImmune (United States).

  1. 1 David Langan United States · #1,386,598 worldwide 350 citations · 18 works
  2. 2 Lauren Suarez United States · #1,616,238 worldwide 320 citations · 49 works
All ranked researchers at NexImmune (United States)

What are the most cited papers from NexImmune (United States)?

The most cited paper from NexImmune (United States) is "Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study" (Christopher Edward Brightling, Eugene R. Bleecker, Reynold A. Panettieri et al., 2014), with 316 citations. Next come "Characterization of MHC class I restricted cytotoxic T cell responses to tax in HTLV-1 infected patients with neurologic disease." (99) and "A randomised, placebo-controlled trial of anti–interleukin-1 receptor 1 monoclonal antibody MEDI8968 in chronic obstructive pulmonary disease" (97).

Most cited papers
#PaperReleasedCitations
1 Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study Christopher Edward Brightling, Eugene R. Bleecker, Reynold A. Panettieri et al. · The Lancet Respiratory Medicine Open access 7 Sep 2014 316
2 Characterization of MHC class I restricted cytotoxic T cell responses to tax in HTLV-1 infected patients with neurologic disease. Scott Koenig, Robert M. Woods, Yambasu A. Brewah et al. · The Journal of Immunology Oct 1993 99
3 A randomised, placebo-controlled trial of anti–interleukin-1 receptor 1 monoclonal antibody MEDI8968 in chronic obstructive pulmonary disease Peter M.A. Calverley, Sanjay Sethi, Michelle Dawson et al. · Respiratory Research Open access 9 Aug 2017 97
4 Two first-in-human, open-label, phase I dose-escalation safety trials of MEDI-528, a monoclonal antibody against interleukin-9, in healthy adult volunteers BARBARA W. WHITE, Francisco León, Wendy I. White et al. · Clinical Therapeutics Apr 2009 75
5 Rapid Expansion of Highly Functional Antigen-Specific T Cells from Patients with Melanoma by Nanoscale Artificial Antigen-Presenting Cells Junya Ichikawa, Tatsuya Yoshida, Ariel Isser et al. · Clinical Cancer Research Open access 2 Apr 2020 47
All 20 most cited papers, with filters and sorting

Which research topics does NexImmune (United States) publish most on?

By volume in 2022-now: CAR-T cell therapy research, Immunotherapy and Immune Responses, Immune Cell Function and Interaction and Endoplasmic Reticulum Stress and Disease.

CAR-T cell therapy resea…1CAR-T cell therapy research: 1 fractional worksImmunotherapy and Immune…1Immunotherapy and Immune Responses: 1 fractional worksImmune Cell Function and…0Immune Cell Function and Interaction: 0 fractional worksEndoplasmic Reticulum Stress and Disease: 0 fractional worksMicrobial metabolism and enzyme function: 0 fractional worksT-cell and B-cell Immunology: 0 fractional worksVirus-based gene therapy research: 0 fractional worksCytomegalovirus and herpesvirus research: 0 fractional worksvaccines and immunoinformatics approaches: 0 fractional worksAdvanced Glycation End P…0Advanced Glycation End Products research: 0 fractional works
OncologyImmunologyCell BiologyMolecular Biology3 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 CAR-T cell therapy research Oncology 1 works
  2. 2 Immunotherapy and Immune Responses Immunology 1 works
  3. 3 Immune Cell Function and Interaction Immunology 0 works
  4. 4 Endoplasmic Reticulum Stress and Disease Cell Biology 0 works
  5. 5 Microbial metabolism and enzyme function Molecular Biology 0 works
  6. 6 T-cell and B-cell Immunology Immunology 0 works
  7. 7 Virus-based gene therapy research Genetics 0 works
  8. 8 Cytomegalovirus and herpesvirus research Epidemiology 0 works
  9. 9 vaccines and immunoinformatics approaches Molecular Biology 0 works
  10. 10 Advanced Glycation End Products research Clinical Biochemistry 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available52.5%not open47.5%

World: 40% of research is openly available.

with international co-authors14.7%domestic only85.3%

World: 18% is written across borders.

How has NexImmune (United States)'s research output changed?

Output in 2022-2025 was 1% lower than in 2018-2021.

still counting200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is NexImmune (United States) as a percentage of every work published that year, 0.0000087% in 2024.

still counting0.000050%0.00010%NexImmune (United States)0.000021% in 2025200020102020

Fractional works of NexImmune (United States) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Gaithersburg

All research institutions in Gaithersburg

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about NexImmune (United States). Posts are plain text and can be reported.